Screener
Integra LifeSciences IART Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Preferred stock; no par value; 15,000 authorized shares; none outstanding | — | — |
| Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively | 921 | 923 |
| Additional paid-in capital | 1,346,265 | 1,338,386 |
| Treasury stock, at cost; 14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively | (686,918) | (689,210) |
| Accumulated other comprehensive loss | (40,197) | (30,077) |
| Retained earnings | 423,306 | 423,441 |
| Total stockholders’ equity | 1,043,377 | 1,043,463 |
| Total liabilities and stockholders’ equity | $3,563,490 | $3,602,001 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's total equity?
- Integra LifeSciences (IART) reported total equity of $1.04B in Q2 2026.
- How has Integra LifeSciences's total equity changed year-over-year?
- Integra LifeSciences's total equity increased by 0.5% year-over-year, from $1.04B to $1.04B.
- What is the long-term trend for Integra LifeSciences's total equity?
- Over 5 years (2020 to 2025), Integra LifeSciences's total equity has grown at a -7.2% compound annual growth rate (CAGR), from $1.51B to $1.04B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Integra LifeSciences's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude